

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

**Table S1.** Shares of seropositive and seronegative individuals by age and seromonitoring stage

Age group, years	Value, % (95% confidence interval)			
	Nc-RBD-	Nc+RBD-	RBD+Nc-	Nc+RBD+
Stage 1				
1–17	34.6 (30.6–38.7)	5.3 (3.6–7.5)	22.1 (18.7–25.8)	38.0 (33.9–42.2)
18–29	38.7 (33.9–43.6)	3.7 (2.1–6.0)	29.8 (25.4–34.5)	27.8 (25.3–32.5)
30–39	36.6 (32.9–40.4)	4.4 (2.9–6.2)	27.7 (24.3–31.3)	31.3 (27.8–35.0)
40–49	33.2 (30.0–36.5)	4.6 (3.3–6.3)	25.5 (22.5–28.6)	36.7 (33.4–40.1)
50–59	26.9 (23.8–30.1)	7.2 (5.5–9.2)	19.4 (16.7–22.4)	46.5 (43.0–50.1)
60–69	32.0 (28.5–35.6)	6.2 (4.6–8.3)	15.2 (12.6–18.1)	46.6 (42.9–50.4)
70 <sup>+</sup>	27.5 (24.3–30.9)	5.2 (3.7–7.1)	22.6 (19.6–25.8)	44.7 (41.1–48.4)
OVERALL	32.2 (30.8–33.5)	5.4 (5.1–6.1)	22.7 (21.7–24.0)	39.7 (38.4–41.2)
Stage 2				
1–17	30.7 (26.9–34.8)	2.9 (1.7–4.7)	42.1 (37.9–46.3)	24.3 (20.8–28.1)
18–29	29.8 (25.4–34.5)	2.2 (1.0–4.2)	47.3 (42.4–52.3)	20.7 (16.8–25.0)
30–39	28.0 (24.6–31.6)	4.7 (3.2–6.6)	42.6 (38.8–46.5)	24.7 (21.5–28.2)
40–49	24.3 (21.4–27.4)	4.9 (3.5–6.6)	42.2 (38.8–45.7)	28.6 (25.6–31.9)
50–59	19.4 (16.7–22.4)	4.0 (2.7–5.5)	36.4 (33.1–40.0)	40.2 (36.8–43.7)
60–69	19.6 (16.7–22.7)	3.4 (2.2–5.0)	35.9 (32.4–39.6)	41.1 (37.4–44.8)
70 <sup>+</sup>	22.0 (19.1–25.2)	2.9 (1.8–4.4)	34.0 (30.5–37.6)	41.1 (37.5–44.8)
OVERALL	24.2 (23.0–25.4)	3.7 (3.2–4.2)	39.5 (38.1–40.9)	32.7 (31.3–34.0)
Stage 3				
1–17	16.1 (13.1–19.4)	2.0 (1.1–3.6)	37.1 (33.1–41.3)	44.8 (40.6–49.1)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

Age group, years	Value, % (95% confidence interval)			
	Nc-RBD-	Nc+RBD-	RBD+Nc-	Nc+RBD+
18–29	15.3 (11.9–19.1)	1.7 (0.7–3.5)	44.3 (39.4–49.3)	38.7 (33.9–43.6)
30–39	13.7 (11.2–16.6)	3.5 (2.2–5.2)	39.6 (35.9–43.4)	43.2 (39.4–47.1)
40–49	11.6 (9.5–14.0)	3.3 (2.2–4.8)	35.8 (32.6–39.2)	49.3 (45.8–52.8)
50–59	10.3 (8.3–12.7)	1.8 (1.0–2.9)	33.0 (29.8–36.4)	54.9 (51.3–59.4)
60–69	9.2 (7.2–11.6)	2.3 (1.3–3.7)	33.5 (30.0–37.1)	55.0 (51.2–58.7)
70 <sup>+</sup>	11.3 (9.1–13.8)	2.1 (1.1–3.4)	33.0 (29.6–36.6)	53.6 (49.9–57.3)
OVERALL	12.1 (11.2–13.1)	2.4 (2.0–2.9)	36.0 (34.6–37.4)	49.5 (48.0–50.9)
Stage 4				
1–17	1.8 (0.9–3.3)	2.9 (1.7–4.7)	13.0 (10.3–16.1)	82.3 (78.8–85.4)
18–29	2.0 (0.8–3.8)	2.7 (1.4–4.8)	15.7 (12.4–19.7)	79.6 (75.3–83.4)
30–39	2.9 (1.7–4.4)	2.4 (1.4–3.9)	15.7 (13.0–18.6)	79.0 (75.8–82.1)
40–49	1.1 (0.5–2.1)	1.8 (0.9–2.8)	15.4 (13.0–18.0)	81.7 (78.9–84.3)
50–59	2.0 (1.2–3.3)	1.3 (0.6–2.3)	15.0 (12.6–17.7)	81.7 (78.8–84.4)
60–69	2.6 (1.5–4.0)	2.8 (1.7–4.4)	18.5 (15.7–21.5)	76.1 (72.8–79.2)
70 <sup>+</sup>	2.5 (1.5–3.9)	1.5 (0.8–2.7)	16.5 (13.4–19.4)	79.5 (76.4–82.4)
OVERALL	2.1 (1.7–2.6)	2.1 (1.7–2.6)	15.8 (14.7–16.8)	80.0 (78.8–91.2)

Note for Tables

(S1, S2, S3): Nc<sup>-</sup>RBD<sup>-</sup> — SARS-CoV-2 Ab seronegative individuals; Nc<sup>+</sup>RBD<sup>-</sup> — those seropositive for Nc Abs only; RBD<sup>+</sup>Nc<sup>-</sup> — those seropositive for RBD Abs only; Nc<sup>+</sup>RBD<sup>+</sup> — those seropositive for both Abs.

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

**Table S2.** Shares of seropositive and seronegative individuals by region and seromonitoring stage

Administrative region or city	Value, % (95% confidence interval)			
	Nc-RBD-	Nc+RBD-	RBD+Nc-	NC+RBD+
Stage 1				
Brest	29.6 (26.1–33.4)	6.0 (4.2–6.1)	22.7 (19.5–26.2)	41.7 (37.9–45.6)
Vitebsk	35.7 (34.5–40.0)	5.1 (3.3–7.3)	23.2 (19.6–27.1)	36.0 (31.9–40.4)
Grodno	30.3 (26.6–34.3)	5.7 (4.0–7.0)	19.9 (16.7–23.4)	44.1 (40.0–48.3)
Gomel	32.3 (27.8–37.0)	7.2 (5.0–10.1)	22.7 (18.8–27.1)	37.8 (33.1–42.6)
Mogilev	31.4 (28.6–34.4)	5.2 (3.9–6.7)	25.2 (22.6–28.0)	38.2 (35.2–41.2)
Minsk	33.6 (29.7–37.6)	4.3 (2.8–6.3)	25.1 (21.6–28.8)	37.0 (33.1–41.1)
Minsk city	32.9 (29.9–36.1)	4.9 (3.6–6.5)	20.0 (17.5–22.8)	42.2 (38.9–45.4)
OVERALL	32.2 (30.8–33.5)	5.4 (5.1–6.1)	22.7 (21.6–24.0)	39.7 (38.3–42.2)
Stage 2				
Brest	25.8 (22.4–29.4)	2.6 (1.5–4.2)	39.4 (35.6–43.4)	32.2 (28.5–36.0)
Vitebsk	25.7 (22.0–29.7)	2.7 (1.5–4.5)	42.9 (38.6–47.3)	28.7 (24.5–32.8)
Grodno	25.4 (21.9–29.2)	4.4 (2.8–6.4)	38.8 (34.8–43.0)	31.4 (27.6–35.3)
Gomel	27.8 (23.5–32.3)	7.6 (5.3–10.6)	34.2 (29.7–39.0)	30.4 (26.0–35.0)
Mogilev	22.3 (19.8–25.0)	3.4 (2.4–4.6)	37.5 (34.5–40.5)	36.8 (33.9–39.8)
Minsk	24.1 (20.6–27.8)	4.0 (2.5–5.9)	44.6 (40.5–48.8)	27.3 (23.7–31.2)
Minsk city	21.9 (19.2–24.7)	2.9 (2.0–4.3)	39.4 (36.2–42.6)	35.8 (32.7–39.0)
OVERALL	24.1 (23.0–25.4)	3.7 (3.2–4.3)	39.5 (38.1–40.9)	32.7 (31.3–34.0)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

Administrative region or city	Value, % (95% confidence interval)			
	Nc-RBD-	Nc+RBD-	RBD+Nc-	NC+RBD+
Stage 3				
Brest	13.2 (10.4–19.1)	2.6 (1.5–4.2)	34.4 (30.8–38.3)	49.8 (45.8–53.8)
Vitebsk	11.7 (9.0–14.8)	2.3 (1.2–4.1)	38.6 (34.4–43.0)	47.4 (43.0–51.8)
Grodno	14.5 (11.7–17.6)	3.7 (2.3–5.5)	36.2 (32.3–40.3)	45.6 (41.5–49.8)
Gomel	9.8 (7.1–13.1)	2.9 (1.5–5.0)	34.0 (29.4–38.7)	53.3 (48.4–58.2)
Mogilev	11.7 (9.8–13.8)	2.2 (1.4–3.3)	36.0 (33.0–40.0)	50.1 (47.1–53.2)
Minsk	13.1 (10.5–16.2)	1.2 (0.5–2.5)	38.8 (34.5–42.9)	46.9 (42.8–51.1)
Minsk	11.0 (9.1–13.3)	2.4 (1.5–3.6)	34.7 (31.6–37.9)	51.9 (48.6–55.1)
OVERALL	12.1 (11.2–13.1)	2.4 (2.0–2.9)	36.0 (34.6–37.4)	49.5 (48.0–50.9)
Stage 4				
Brest	2.7 (1.5–4.2)	2.7 (1.6–4.4)	15.4 (12.7–18.6)	79.2 (75.8–82.4)
Vitebsk	2.3 (1.2–4.1)	1.9 (0.9–3.6)	17.0 (13.8–20.5)	78.8 (75.0–82.2)
Grodno	1.9 (1.0–3.4)	3.0 (1.7–4.7)	13.2 (10.6–16.2)	81.9 (78.5–85.0)
Gomel	1.9 (0.8–3.7)	1.0 (0.2–2.4)	19.1 (15.5–23.2)	78.0 (73.7–81.9)
Mogilev	1.9 (1.2–3.0)	2.4 (1.6–3.5)	17.7 (15.5–20.2)	78.0 (75.3–80.4)
Minsk	1.7 (0.8–3.2)	2.1 (1.1–3.6)	15.6 (12.7–18.8)	80.6 (77.2–83.8)
Minsk	2.4 (1.5–3.6)	1.5 (0.8–2.4)	13.1 (11.0–15.5)	83.0 (80.4–85.4)
OVERALL	2.1 (1.7–2.6)	2.1 (1.7–2.6)	15.8 (14.7–16.8)	80.0 (78.9–81.2)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

**Table S3.** Shares of seropositive and seronegative individuals by professional category

Occupational Group	Value, % (95% confidence interval)			
	Nc-RBD-	Nc+RBD-	RBD+Nc-	NC+RBD+
Stage 1				
Health workers	22.5 (19.4–25.7)	4.8 (3.4–6.7)	33.9 (30.4–37.6)	38.8 (35.1–42.5)
Scientists	25.7 (12.5–43.3)	2.9 (0.07–14.9)	31.4 (16.8–49.3)	40.0 (23.9–57.9)
Business	42.3 (35.2–49.7)	6.4 (3.3–10.8)	18.0 (12.8–24.2)	33.3 (26.7–40.5)
Education	29.1 (24.8–33.6)	5.8 (3.8–8.5)	25.1 (21.1–29.5)	40.0 (35.3–44.8)
The Arts	38.2 (25.4–52.3)	3.7 (0.4–12.5)	25.4 (14.7–39.0)	32.7 (20.7–46.7)
Industry	36.4 (31.9–41.1)	5.0 (3.2–7.5)	20.0 (16.4–24.1)	38.6 (34.1–43.4)
Transport	27.7 (19.3–37.5)	10.9 (5.6–18.6)	23.8 (15.9–33.3)	37.6 (28.1–47.8)
Military employees	26.7 (12.3–45.9)	6.6 (0.8–22.1)	10.0 (2.1–26.5)	56.7 (37.4–74.5)
Civil servants	25.8 (18.4–34.4)	4.8 (1.8–10.2)	16.1 (10.1–23.8)	53.3 (44.1–62.2)
Office workers	36.3 (32.5–40.3)	5.4 (3.8–7.6)	19.8 (16.7–23.2)	38.5 (34.6–42.4)
Unemployed	42.2 (31.9–53.1)	8.9 (3.9–16.8)	20.0 (12.3–29.8)	28.9 (19.8–39.4)
Children	58.8 (44.2–72.4)	3.9 (0.5–13.5)	15.7 (7.0–28.6)	21.6 (11.3–35.3)
Other	36.4 (30.6–42.3)	3.5 (1.6–6.5)	24.0 (19.0–29.7)	36.1 (30.2–42.2)
Schoolchildren	32.5 (28.1–37.1)	4.7 (2.9–7.1)	23.1 (19.2–27.4)	39.7 (35.1–44.5)
Students	41.3 (27.0–56.8)	4.3 (0.5–14.8)	26.1 (14.3–41.1)	28.3 (16.0–43.5)
Pensioners	31.4 (28.7–34.3)	5.7 (4.4–7.2)	18.7 (16.4–21.2)	44.2 (41.2–47.2)
OVERALL	32.2 (30.8–33.5)	5.4 (5.1–6.1)	22.7 (21.6–24.0)	39.7 (38.3–41.2)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

<b>Occupational Group</b>	<b>Value, % (95% confidence interval)</b>			
	<b>Nc-RBD-</b>	<b>Nc+RBD-</b>	<b>RBD+Nc-</b>	<b>NC+RBD+</b>
<b>Stage 2</b>				
Health workers	17.9 (15.1–20.9)	2.4 (1.4–3.9)	46.9 (43.1–50.7)	32.8 (29.3–36.4)
Scientists	25.7 (12.5–43.3)	2.9 (0.7–14.9)	37.1 (21.5–55.1)	34.3 (19.1–52.2)
Business	30.7 (24.2–37.8)	3.7 (1.5–7.5)	37.6 (30.6–44.9)	28.0 (21.8–35.0)
Education	19.5 (15.9–23.6)	3.0 (1.6–5.1)	44.2 (39.4–42.0)	33.3 (28.8–37.9)
The Arts	25.5 (14.7–39.0)	3.6 (0.4–12.5)	41.8 (2.9–55.9)	29.1 (17.6–42.9)
Industry	23.9 (20.0–28.1)	5.2 (3.3–7.7)	41.6 (36.9–46.4)	29.3 (25.1–33.8)
Transport	20.8 (13.4–30.1)	13.9 (7.8–22.2)	33.7 (24.6–43.8)	31.7 (22.8–41.7)
Military employees	20.0 (7.7–38.6)	13.3 (3.8–30.7)	23.3 (9.9–42.3)	43.3 (25.5–62.6)
Civil servants	23.4 (16.3–31.8)	4.0 (1.3–9.2)	29.0 (21.2–37.9)	43.6 (34.7–52.7)
Office workers	28.0 (24.5–31.8)	3.6 (2.3–5.5)	38.0 (34.1–42.0)	30.4 (26.7–34.2)
Unemployed	30.0 (20.8–40.6)	4.4 (1.2–11.0)	35.6 (25.7–43.4)	30.0 (20.8–40.6)
Children	45.1 (31.1–60.0)	2.0 (0.5–10.4)	31.3 (19.1–45.9)	21.6 (11.3–35.3)
Other	25.6 (20.4–31.4)	4.7 (2.4–8.0)	39.9 (33.9–46.2)	29.8 (24.3–35.8)
Schoolchildren	29.7 (25.4–34.2)	3.3 (1.8–5.4)	42.5 (37.8–47.4)	24.5 (20.5–28.9)
Students	26.1 (14.3–41.1)	2.1 (0.6–11.5)	52.2 (3.7–6.7)	19.6 (9.4–33.9)
Pensioners	23.2 (20.7–25.8)	2.9 (2.0–4.2)	34.1 (31.3–37.0)	39.8 (36.8–42.7)
<b>OVERALL</b>	24.1 (23.0–25.4)	3.7 (3.2–4.3)	39.5 (38.1–40.9)	32.7 (31.3–34.0)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

<b>Occupational Group</b>	<b>Value, % (95% confidence interval)</b>			
	<b>Nc-RBD-</b>	<b>Nc+RBD-</b>	<b>RBD+Nc-</b>	<b>NC+RBD+</b>
Stage 3				
Health workers	9.0 (7.1–11.4)	1.7 (0.9–3.0)	40.1 (36.4–43.8)	49.2 (45.5–52.9)
Scientists	2.8 (0.7–14.9)	0	54.3 (36.6–71.2)	42.9 (26.3–60.6)
Business	14.8 (10.1–20.7)	4.2 (1.8–8.2)	34.4 (27.6–41.6)	46.6 (39.3–53.9)
Education	11.4 (8.6–14.8)	2.6 (1.3–4.5)	39.3 (34.7–44.1)	46.7 (42.0–51.6)
The Arts	14.5 (6.5–26.7)	1.8 (0.05–9.7)	36.4 (23.8–50.4)	47.3 (33.6–61.2)
Industry	12.1(9.2–15.5)	2.1 (0.9–3.8)	35.2 (30.8–39.9)	50.7 (45.9–55.5)
Transport	6.9 (2.8–13.8)	4.0 (1.1–9.8)	37.6 (28.2–47.8)	51.5 (41.3–61.6)
Military employees	6.7 (0.8–22.1)	3.3 (0.08–13.2)	36.7 (19.9–56.1)	53.3 (34.3–71.7)
Civil servants	8.9 (4.5–15.3)	2.4 (0.5–6.9)	31.4 (23.4–40.4)	57.3 (48.1–66.1)
Office workers	13.7 (11.1–16.7)	2.8 (1.6–4.4)	32.0 (28.3–35.9)	51.5 (47.4–55.5)
Unemployed	12.2 (6.3–20.8)	1.1 (0.03–6.0)	36.7 (26.8–47.5)	50.0 (39.3–60.7)
Children	25.5 (14.3–39.6)	2.0 (0.1–10.5)	37.2 (24.1–51.9)	35.3 (22.4–49.9)
Other	14.0 (10.0–18.8)	3.9 (1.9–7.0)	38.0 (32.0–44.2)	44.1 (38.0–50.5)
Schoolchildren	15.0 (11.7–18.7)	2.1 (1.0–4.0)	37.2 (32.6–41.9)	45.8 (41.0–50.6)
Students	8.7 (2.4–20.8)	0	56.5 (41.1–71.1)	34.8 (21.4–50.2)
Pensioners	12.2 (10.3–14.3)	2.4 (1.6–3.5)	32.7 (29.9–35.6)	52.6 (49.6–55.7)
<b>OVERALL</b>	12.1 (11.2–13.1)	2.4 (2.0–2.9)	36.0 (34.6–37.4)	49.5 (48.0–50.4)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

<b>Occupational Group</b>	<b>Value, % (95% confidence interval)</b>			
	<b>Nc-RBD-</b>	<b>Nc+RBD-</b>	<b>RBD+Nc-</b>	<b>NC+RBD+</b>
Stage 4				
Health workers	1.4 (0.7–2.6)	1.4 (0.7–2.6)	19.0 (16.2–22.1)	78.1 (74.9–81.1)
Scientists	0	0	25.7 (12.5–43.3)	74.3 (56.7–87.5)
Business	2.1 (0.6–5.3)	1.6 (0.3–4.6)	16.4 (11.4–22.5)	79.9 (73.5–85.4)
Education	0.9 (0.2–2.4)	2.1 (1.0–3.9)	15.1 (11.7–18.9)	81.9 (77.9–85.4)
the Arts	3.6 (0.4–12.5)	3.6 (0.4–12.5)	14.6 (6.5–26.7)	78.2 (65.0–88.2)
Industry	2.5 (1.3–4.4)	0.9 (0.2–2.3)	13.9 (10.8–17.4)	82.7 (78.9–86.1)
Transport	1.0 (0.03–5.4)	3.0 (0.6–8.4)	14.8 (8.6–23.3)	81.2 (72.2–88.3)
Military employees	0	0	16.7 (5.6–34.7)	83.3 (65.3–94.4)
Civil servants	0	3.2 (0.9–8.1)	11.3 (6.3–18.2)	85.5 (78.0–91.2)
Office workers	2.8 (1.6–4.4)	2.2 (1.2–3.6)	13.5 (10.9–16.5)	81.5 (78.2–84.5)
Unemployed	0	2.2 (0.3–7.8)	15.6 (8.7–24.7)	82.2 (72.7–89.5)
Children	2.0 (0.05–10.4)	7.8 (2.2–18.9)	11.8 (4.4–23.9)	78.4 (64.5–88.7)
Other	1.9 (0.6–4.5)	1.6 (0.4–3.9)	20.9 (16.1–26.4)	75.6 (70.0–80.7)
Schoolchildren	1.9 (0.8–3.6)	2.8 (1.5–4.8)	11.0 (8.2–14.3)	84.3 (80.6–87.7)
Students	0	0	13.0 (4.9–26.3)	87.0 (73.7–95.1)
Pensioners	3.2 (2.3–4.5)	2.7 (1.8–3.8)	17.1 (14.8–19.4)	77.0 (74.4–79.5)
<b>OVERALL</b>	2.1 (1.7–2.6)	2.1 (1.7–2.6)	15.8 (14.7–16.8)	80.0 (78.8–81.2)



**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

**Table S4.** Distributions by volunteer Nc Ab level and age

Age group, years	Antibody interval, BAU/ml				
	16.8–31.2 % (95% CI)	31.3–125.6 % (95% CI)	125.8–251.2 % (95% CI)	251.4–502.5 % (95% CI)	>502.5 % (95% CI)
Stage 1					
1–17	13.7 (10.9–16.9)	21.8 (18.4–25.4)	5.7 (3.9–8.0)	1.3 (0.5–2.6)	0.7 (0.2–1.9)
18–29	9.8 (7.1–13.2)	17.0 (16.1–22.2)	2.5 (1.2–4.5)	1.2 (0.4–2.8)	1 (0.3–2.5)
30–39	9.3 (7.2–11.8)	19.0 (16.1–22.2)	4.7 (3.2–6.6)	2.1 (1.2–3.5)	0.6 (0.2–1.5)
40–49	9.5 (7.6–11.7)	20.5 (17.8–23.4)	6.8 (5.2–8.8)	2.9 (1.9–4.3)	1.6 (0.7–2.7)
50–59	11.3 (9.2–13.8)	25.6 (22.6–28.8)	9.6 (7.6–11.8)	4.2 (2.9–5.8)	3 (2.0–4.5)
60–69	7.8 (5.9–10.1)	22.3 (19.3–25.6)	11.8 (9.5–14.4)	6.1 (4.5–8.1)	4.8 (3.3–6.7)
70 <sup>+</sup>	6.9 (5.2–9.0)	20.6 (17.8–24.8)	10.4 (8.3–12.9)	7.7 (5.9–9.9)	4.3 (2.9–6.0)
OVERALL	9.7 (8.8–10.5)	21.3 (20.1–22.5)	7.8 (7.1–8.6)	3.9 (3.4–4.5)	2.5 (2.2–3.0)
Stage 2					
1–17	9.1 (6.9–11.9)	14.1 (11.3–17.3)	2.6 (1.4–4.3)	0.7 (0.2–1.9)	0.7 (0.2–1.9)
18–29	9.6 (6.9–12.1)	8.9 (6.3–12.1)	2.7 (1.4–4.8)	1.2 (0.4–2.8)	0.5 (0.1–1.8)
30–39	10.4 (8.2–13.0)	13.7 (11.2–16.6)	3.3 (2.1–5.0)	1.1 (1.1–2.2)	0.9 (0.3–2.0)
40–49	10.4 (8.4–12.7)	16.1 (13.6–18.8)	4.5 (3.2–6.2)	1.5 (0.8–2.5)	1.1 (0.5–2.1)
50–59	11.6 (9.5–14.4)	23.1 (20.2–26.2)	6.3 (4.7–8.2)	2.4 (1.4–3.7)	0.8 (0.3–1.6)
60–69	10.6 (8.5–13.2)	20.9 (17.9–24.1)	7.4 (5.6–9.6)	3.7 (2.4–5.4)	1.8 (1.0–3.1)
70 <sup>+</sup>	10.4 (8.3–12.9)	20.5 (17.6–23.6)	7.7 (5.9–9.9)	2.9 (1.8–4.4)	2.5 (1.5–2.9)
OVERALL	10.4 (9.6–11.3)	17.5 (16.4–18.6)	5.2 (4.6–5.9)	2.0 (1.6–2.5)	1.2 (1.0–1.6)
Stage 3					

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

Age group, years	Antibody interval, BAU/ml				
	16.8–31.2 % (95% CI)	31.3–125.6 % (95% CI)	125.8–251.2 % (95% CI)	251.4–502.5 % (95% CI)	>502.5 % (95% CI)
1–17	10.1 (7.7–12.9)	21.2 (17.8–24.9)	8.2 (6.1–10.8)	3.1 (1.8–4.9)	4.2 (2.7–6.2)
18–29	9.6 (6.9–12.9)	18.5 (14.8–22.6)	4.9 (3.0–7.5)	3.4 (1.9–5.7)	3.9 (2.3–6.3)
30–39	14.1 (11.5–16.9)	20.3 (14.3–23.6)	5.4 (3.8–7.4)	3.0 (1.8–4.6)	3.9 (2.6–5.7)
40–49	12.6 (10.4–15.0)	23.9 (21.0–27.0)	7.8 (6.1–9.9)	4.0 (2.8–5.6)	4.3 (3.0–5.9)
50–59	10.5 (8.4–12.8)	28.0 (24.9–31.2)	7.8 (6.1–9.9)	5.3 (3.8–7.1)	5.0 (3.6–6.8)
60–69	11.1 (8.8–13.6)	24.2 (21.0–27.5)	9.5 (7.4–11.9)	6.4 (4.7–8.5)	6.1 (4.5–8.1)
70 <sup>+</sup>	10.7 (8.6–13.2)	23.8 (20.7–27.1)	8.2 (6.4–10.5)	6.3 (4.7–8.4)	6.6 (4.9–8.7)
OVERALL	11.4 (10.5–12.3)	23.3 (22.1–24.6)	7.6 (6.9–8.4)	4.7 (3.2–5.3)	5.0 (3.9–5.6)
Stage 4					
1–17	11.0 (8.5–13.9)	34.4 (30.4–38.5)	20.3 (17.0–23.9)	11.2 (8.6–14.1)	8.4 (6.2–11.1)
18–29	15.3 (11.9–19.1)	36.7 (32.0–41.6)	17.2 (13.7–21.0)	7.9 (5.4–10.0)	5.2 (3.2–7.8)
30–39	13.9 (11.3–16.7)	38.7 (35.0–42.5)	14.5 (11.9–17.4)	7.7 (5.8–10.0)	6.8 (5.0–9.0)
40–49	14.8 (12.4–17.4)	33.8 (30.6–37.1)	16.0 (14.0–18.7)	11.3 (9.2–13.7)	7.7 (6.0–9.7)
50–59	12.4 (10.2–14.8)	32.3 (29.0–35.7)	16.6 (14.1–19.4)	7.8 (6.1–9.9)	13.9 (11.5–16.5)
60–69	11.9 (9.6–14.6)	31.7 (28.2–35.3)	14.6 (12.1–20.1)	9.1 (7.1–11.5)	11.6 (9.4–14.2)
70 <sup>+</sup>	10.4 (8.3–12.9)	34.7 (31.2–38.2)	17.2 (14.5–20.1)	8.2 (6.4–10.5)	10.4 (8.3–12.9)
OVERALL	12.7 (11.8–13.7)	34.4 (33.0–35.8)	16.5 (15.4–17.6)	9.1 (8.3–9.9)	9.5 (8.7–10.4)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

**Table S5.** Distributions by volunteer RBD Ab level and age

Age group, years	Antibody interval, BAU/ml		
	22.6–220 % (95% CI)	221–450 % (95% CI)	>450 % (95% CI)
Stage 1			
1–17	44.6 (40.4–48.8)	8.8 (6.5–11.5)	6.8 (4.8–9.2)
18–29	36.7 (32.0–41.6)	8.6 (6.1–11.8)	12.3 (9.3–15.9)
30–39	39.5 (35.7–43.3)	9.6 (7.5–12.1)	9.9 (7.8–12.5)
40–49	39.0 (32.7–42.5)	8.7 (6.8–10.8)	14.5 (12.2–17.7)
50–59	33.7 (30.4–37.1)	13.2 (11.0–15.8)	19.0 (17.1–22.7)
60–69	26.4 (23.2–29.8)	13.8 (11.3–16.6)	21.6 (18.6–24.8)
70 <sup>+</sup>	30 (26.7–33.5)	14.2 (11.7–16.9)	23.1 (20.1–26.4)
OVERALL	35.3 (34.0–36.7)	11.2 (10.3–12.2)	15.9 (14.2–17.0)
Stage 2			
1–17	49.3 (45.0–53.7)	8.3 (6.1–11.0)	9.1 (6.8–11.8)
18–29	41.7 (36.8–46.7)	8.0 (5.6–11.2)	17.6 (14.0–21.7)
30–39	40.1 (36.2–44.0)	9.8 (7.6–12.3)	17.7 (14.8–20.9)
40–49	37.6 (34.2–41.0)	11.8 (9.6–14.2)	21.2 (18.4–24.2)
50–59	38.7 (35.3–42.2)	12.7 (10.4–15.3)	25.4 (22.3–28.6)
60–69	36.7 (34.4–41.6)	13.4 (10.9–16.1)	25.0 (21.8–28.4)
70 <sup>+</sup>	37.9 (34.4–41.6)	13.7 (11.3–16.5)	20.6 (17.7–23.7)
OVERALL	39.8 (38.4–41.2)	11.5 (10.6–12.4)	20.2 (19.1–21.4)

**SUPPLEMENTARY MATERIALS FOR ARTICLE ID 14440**  
**(Russian Journal of Infection and Immunity)**

Stage 3			
1–17	53.41 (49.1–57.7)	13.1 (10.4–16.2)	16.0 (13.0–19.4)
18–29	40.0 (35.2–45.0)	18.3 (14.6–22.4)	24.9 (20.8–29.4)
30–39	40.5 (36.7–44.3)	20.2 (17.2–23.5)	22.4 (19.2–25.7)
40–49	37.6 (34.3–41.1)	18.1 (15.5–20.9)	29.6 (26.5–32.8)
50–59	34.5 (31.2–37.9)	17.8 (15.2–20.6)	35.7 (32.4–39.2)
60–69	34.8 (31.3–38.4)	14.6 (12.1–17.5)	39.1 (35.4–42.8)
70 <sup>+</sup>	35 (31.5–38.6)	15.8 (13.3–18.7)	36.0 (32.4–39.6)
OVERALL	38.7 (37.3–40.1)	16.9 (15.8–18.1)	30.0 (28.7–31.4)
Stage 4			
1–17	33.8 (29.9–38.0)	25.6 (22.0–29.5)	35.8 (31.8–40.0)
18–29	28.8 (24.5–33.5)	28.3 (24.0–33.0)	38.2 (33.4–43.1)
30–39	27.7 (24.3–31.3)	23.0 (19.6–25.5)	44.0 (40.2–47.8)
40–49	23.7 (20.8–26.8)	22.5 (19.6–25.5)	51.0 (47.5–54.6)
50–59	18.4 (15.7–21.3)	18.7 (16.1–21.6)	59.6 (56.1–63.1)
60–69	16.8 (14.1–19.7)	17.9 (15.1–20.9)	59.9 (56.2–65.4)
70 <sup>+</sup>	19.1 (16.3–22.2)	19.1 (16.3–22.2)	57.8 (54.1–61.4)
OVERALL	23.2 (22.1–24.5)	21.6 (20.4–22.8)	51.0 (49.6–52.4)